logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
D

Dirk Strumberg

Ruhr University Bochum
H指数:48
被引数:9,665

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

International testing and refinement of AI algorithms predicting acute leukemia subtypes from routine laboratory data

从常规实验室数据中预测急性白血病亚型的AI算法的国际测试和改进

Nature Communications
IF15.7
2026-03-200
OAAI
Amin T. Turki; Yi Fan; Alberto Hernández-Sánchez; Wellington Silva; Shaun Fleming; Koray Yalcin; Catharina H.M.J. Van Elssen; Yazan Madanat; Magdalena Karasek; Mahmoud Aljurf; Matteo G. Della Porta; Alexandra Martinez-Roca; Luca Guarnera; Katarina Steffen; Evangelia Antoniou; Maria M. Rivas; Deepak K. Mishra; Ansgar T. Blum; Stephania Niry Manantsoa; Adeniyi Adiat; Amir Enshaei; Felicitas Thol; Maria Teresa Voso; Jia Chen; Tusneem Ahmed Elhassan; Anthony V. Moorman; María Belén Vidriales; Nina R. Neuendorff; Ahmet Koc; Pratyush Mishra; Dirk Strumberg; Roma S. Fourmanov; Lukas Heine; Jens Kleesiek; Daniel Munárriz; Gianluca Asti; Mridula Mokoonlall; Marisa Kometas; Eduardo Rego; Rabea Mecklenbrauck; Marta Sobas; Depei Wu; Felix Nensa; Merlin Engelke
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

维奈克拉-obinutuzumab在CLL中，体能和剂量强度对临床结局的影响

Blood
IF23.1
2025-08-290
OAAI
Othman Al-Sawaf; Moritz Fürstenau; Adam Giza; Sandra Robrecht; Julia von Tresckow; Anna-Maria Fink; Florian Simon; Eugen Tausch; Christof Schneider; Liliya Sivcheva; Anthony Schwarer; Javier Loscertales; Robert Weinkove; Dirk Strumberg; Allanah Kilfoyle; Gunnar Juliusson; Caspar da Cunha-Bang; Thomas Illmer; Michael Gregor; Patrick Thornton
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

维奈克拉-奥比妥珠单抗在CLL中，体能和剂量强度对临床结局的影响

Blood
IF23.1
2025-08-290
OAAI
Othman Al-Sawaf; Moritz Fürstenau; Adam Giza; Sandra Robrecht; Julia von Tresckow; Anna-Maria Fink; Florian Simon; Eugen Tausch; Christof Schneider; Liliya Sivcheva; Anthony Schwarer; Javier Loscertales; Robert Weinkove; Dirk Strumberg; Allanah Kilfoyle; Gunnar Juliusson; Caspar da Cunha-Bang; Thomas Illmer; Michael Gregor; Patrick Thornton
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM
INTERNATIONAL JOURNAL OF CANCER
IF4.7
2023-03-2313
PRE
Goetze, Thorsten O.; Hofheinz, Ralf-Dieter; Gaiser, Timo; Schmalenberg, Harald; Strumberg, Dirk; Goekkurt, Eray; Angermeier, Stefan; Zander, Thomas; Kopp, Hans G.; Pink, Daniel; Siegler, Gabriele; Schenk, Michael; de Vita, Ferdinando; Galizia, Gennaro; Maiello, Evaristo; Bechstein, Wolf O.; Elshafei, Moustafa; Loose, Maria; Sookthai, Disorn; Brulin, Tanita; Pauligk, Claudia; Homann, Nils; Al-Batran, Salah-Eddin
Enhanced antitumoral activity of TLR7 agonists via activation of human endogenous retroviruses by HDAC inhibitors
COMMUNICATIONS BIOLOGY
IF5.1
2021-03-0319
OAAI
Diaz-Carballo, David; Saka, Sahitya; Acikelli, Ali H.; Homp, Ekaterina; Erwes, Julia; Demmig, Rebecca; Klein, Jacqueline; Schroeer, Katrin; Malak, Sascha; D'Souza, Flevy; Noa-Bolano, Adrien; Menze, Saskia; Pano, Emilio; Andrioff, Swetlana; Teipel, Marc; Dammann, Philip; Klein, Diana; Nasreen, Amber; Tannapfel, Andrea; Grandi, Nicole; Tramontano, Enzo; Ochsenfarth, Crista; Strumberg, Dirk
Perioperative FLOT plus ramucirumab versus FLOT alone for resectable esophagogastric adenocarcinoma- Updated results and subgroup analyses of the randomized phase II/III trial RAMSES/FLOT7 of the German AIO and Italian GOIM
ANNALS OF ONCOLOGY
IF65.4
2020-09-015
OAAI
Al-Batran, S-E.; Hofheinz, R. D.; Schmalenberg, H.; Strumberg, D.; Goekkurt, E.; Angermeier, S.; Zander, T.; Potenberg, J.; Kopp, H-G.; Pink, D.; Siegler, G. M.; Schenk, M.; De Vita, F.; Maiello, E.; Gaiser, T.; Sookthai, D.; Bankstahl, U. S.; Pauligk, C.; Goetze, T. O.; Homann, N.
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study

吉西他滨联合单克隆抗体尼妥珠单抗是KRAS野生型局部晚期或转移性胰腺癌患者的一线治疗方案: 一项多中心、随机IIb期研究

ANNALS OF ONCOLOGY
IF65.4
2017-10-01119
OAAI
Schultheis, B.; Reuter, D.; Ebert, M. P.; Siveke, J.; Kerkhoff, A.; Berdel, W. E.; Hofheinz, R.; Behringer, D. M.; Schmidt, W. E.; Goker, E.; De Dosso, S.; Kneba, M.; Yalcin, S.; Overkamp, F.; Schlegel, F.; Dommach, M.; Rohrberg, R.; Steinmetz, T.; Bulitta, M.; Strumberg, D.
Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies
BRITISH JOURNAL OF CANCER
IF6.8
2017-05-0224
OAAI
Bahleda, Rastislav; Grilley-Olson, Juneko E.; Govindan, Ramaswamy; Barlesi, Fabrice; Greillier, Laurent; Perol, Maurice; Ray-Coquard, Isabelle; Strumberg, Dirk; Schultheis, Beate; Dy, Grace K.; Zalcman, Gerard; Weiss, Glen J.; Walter, Annette O.; Kornacker, Martin; Rajagopalan, Prabhu; Henderson, David; Nogai, Hendrik; Ocker, Matthias; Soria, Jean-Charles
Therapeutic potential of antiviral drugs targeting chemorefractory colorectal adenocarcinoma cells overexpressing endogenous retroviral elements
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
IF12.8
2015-08-1238
OAAI
Diaz-Carballo, David; Acikelli, Ali Haydar; Klein, Jacqueline; Jastrow, Holger; Dammann, Philipp; Wyganowski, Thomas; Guemues, Cihan; Gustmann, Sebastian; Bardenheuer, Walter; Malak, Sascha; Tefett, Nora Sophia; Khosrawipour, Veria; Giger-Pabst, Urs; Tannapfel, Andrea; Strumberg, Dirk

研究方向

暂未获取到该数据
B
Beate Schultheis
H 指数:39论文数:145被引数:6,199
M
M. E. Scheulen
H 指数:39论文数:311被引数:7,199
S
S. Seeber
H 指数:51论文数:482被引数:1.2万

Yves Pommier
H 指数:138论文数:2,042被引数:8.0万
K
K. Mross
H 指数:39论文数:284被引数:6,546
O
O. Christensen
H 指数:16论文数:51被引数:1,324
J
John L. Nitiss
H 指数:44论文数:143被引数:9,316
W
Wilfried Eberhardt
H 指数:70论文数:497被引数:3.8万
A
Ali H. Acikelli
H 指数:8论文数:47被引数:267
D
David Díaz-Carballo
H 指数:20论文数:70被引数:912